HWM
IONS icon

HighMark Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

HighMark Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-198
Closed -$11K – 494
2020
Q4 		$11K Buy
+198
New +$9.87K 0.01% 213
2020
Q3 		– Sell
-93
Closed -$5K – 460
2020
Q2 		$5K Buy
+93
New +$5.17K 0.01% 311

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HighMark Wealth Management's IONS Position: Q1 2021 in Review

HighMark Wealth Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 198 shares — an estimated $11K sold.

HighMark Wealth Management first reported a position in IONS in Q2 2020 and held it in 2 quarters. The position peaked at $11K in Q4 2020. 365 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

  • HighMark Wealth Management reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • HighMark Wealth Management sold 198 Ionis Pharmaceuticals shares in Q1 2021, an estimated $11K.
  • HighMark Wealth Management first reported a position in Ionis Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • HighMark Wealth Management's Ionis Pharmaceuticals position peaked at $11K in Q4 2020.
  • 365 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on HighMark Wealth Management's 13F filing for Q1 2021, filed 22 Apr 2021.